Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations
Authors:
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 214 (3) , 408-416
Abstract
No abstract availableKeywords
Funding Information
- Deutsches Zentrum für Luft- und Raumfahrt
- Else Kröner-Fresenius-Stiftung
- Universität Heidelberg
- Bundesministerium für Forschung, Technologie und Raumfahrt
This publication has 38 references indexed in Scilit:
- EGFR,KRAS,BRAFandALKgene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotypeEuropean Respiratory Journal, 2013
- Clinical impact of ki-67 labeling index in non-small cell lung cancerLung Cancer, 2013
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- Large‐scale comparative analyses of immunomarkers for diagnostic subtyping of non‐small‐cell lung cancer biopsiesHistopathology, 2012
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung AdenocarcinomaClinical Cancer Research, 2012
- Combined Analysis of Cyclooxygenase-2 Expression With p53 and Ki-67 in Nonsmall Cell Lung CancerThe Annals of Thoracic Surgery, 2006
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Method for grading breast cancer.Journal of Clinical Pathology, 1993